US FDA May Wait Until Late 2019 Before A Cures Hiring Enhancement Is Available
Senior Biomedical Research Service expansion, used to attract elite scientists to federal service, may not be implemented until late 2019; FDA also may have a candidate for OND director.
You may also be interested in...
Human resource managers also worried that since universal teleworking was valued by employees, a return to pre-pandemic conditions could cause a mass exodus.
Sandra Retzky worked at AstraZeneca and in Delaware's Medicaid fraud unit before joining the US FDA in 2016.
OOPD’s deputy director has been named the acting head of the office responsible for orphan and rare pediatric disease designations.